Firefly Luciferase CD19 Knockout Raji Cell Line

Firefly Luciferase CD19 Knockout Raji Cell Line
SKU
BPS82167
Packaging Unit
2 vials
Manufacturer
BPS Bioscience

Availability: loading...
Price is loading...
Products from BPS Bioscience require a minimum order value above 400€

Applications: Use as a control in CAR-T or NK co-culture killing assays In vitro and in vivo bioluminescence imaging

Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cell killing upon co-culture with CAR-T or NK cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Description: Firefly Luciferase CD19 Knockout Raji Cell Line is a Raji cell line constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter, where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD19 Knockout Raji Cell Line (BPS Bioscience #82166).

Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.

Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ~1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Warnings: Avoid freeze/thaw cycle

Biosafety Level: BSL-2
More Information
SKU BPS82167
Manufacturer BPS Bioscience
Manufacturer SKU 82167
Package Unit 2 vials
Quantity Unit PAK
Host Human
Product information (PDF) Download
MSDS (PDF)
×